Medical Devices Leader in a ~70% drawdown

A few days ago, I flagged a wide-moat compounder in its worst drawdown ever (~70% off its highs). The deep dive is now out, and the setup is compelling.

This is a medical device company that has dominated its niche for 40+ years. It holds ~60% of the global market, more than double its closest competitor.

Its product gets surgically implanted into the patient, which means switching to a rival brand literally requires another operation. Once you're a customer, you're a customer for life, typically 30 to 50 years, and every few years you come back for an upgrade. One device sale turns into $30-40k of lifetime revenue per patient.

So why is it down ~70%?

Five things hit at once, and every one of them is temporary: a product transition that stalled deals while hospitals renegotiated contracts, soft consumer sentiment pushing older patients to defer elective surgery, hospital staffing shortages delaying procedures, a government tender pipeline that froze on geopolitics, and an FX headwind.

Notice what's not on that list: anything about its technology, its surgeon relationships, its clinical track record, or its market share. The moat wasn't touched.

The tell is in the competitors. If this company were losing durable share, you'd see rivals gaining. You don't. All three players in the industry are weak right now. The entire end market is in an air pocket, and when it clears, the share leader recovers fastest.

The demand is structural. The condition this treats is permanent, progressive, and medically necessary. It's covered by Medicare, the NHS, the VA, and 90%+ of US commercial insurance. The deferred demand doesn't disappear. It piles up. Meanwhile, the stock trades at ~20x forward earnings, on depressed earnings, a level it has touched only twice in 15 years.

We see ~40% upside to intrinsic value.

Subscribe now to get full access to the deep dive.